A phase l/ll open-label study to assess safety, tolerability and preliminary efficacy of the clever-1 antibody bexmarilimab in combination with azacitidine or azacitidine/venetoclax in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia or acute myeloid leukemia
Principal investigator: Mika Kontro
HUS Helsinki University Hospital, Comprehensive Cancer Center
